Larimar Therapeutics Inc.

AI Score

0

Unlock

3.29
-0.19 (-5.46%)
At close: Jan 14, 2025, 3:59 PM
3.29
-0.15%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 3.1
Market Cap 210.24M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.09
PE Ratio (ttm) -3.02
Forward PE n/a
Analyst Buy
Ask 3.77
Volume 337,760
Avg. Volume (20D) 839,536
Open 3.53
Previous Close 3.48
Day's Range 3.24 - 3.53
52-Week Range 3.01 - 13.68
Beta undefined

About LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania....

Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2014
Employees 42
Stock Exchange NASDAQ
Ticker Symbol LRMR

Analyst Forecast

According to 8 analyst ratings, the average rating for LRMR stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 476.63% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago · Source
-21.72%
Larimar Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
2 months ago · Source
+8.74%
Larimar Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.